Stockreport

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions [Yahoo! Finance]

Evotec SE  (EVO) 
NASDAQ:AMEX Investor Relations: eatonvance.com
PDF its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) ("Evotec") for €11.00 per share in cash, implying a fully diluted equity value of €2.0 billion. Helen Torle [Read more]